Last updated: February 16, 2026
Overview
NDC 24208-0485 corresponds to Zolodex (goserelin acetate) for injectable depot use. Zolodex is primarily indicated for prostate cancer, breast cancer, endometriosis, and central precocious puberty. It plays a significant role in hormone-dependent conditions and oncology, with a mature patent status and established manufacturing channels.
Market Size and Dynamics
Global Market Value (2022): Estimated at approximately $1.3 billion, primarily driven by prostate and breast cancer treatments.[1]
Key Market Segments:
- Prostate Cancer: Accounts for roughly 65% of sales. The drug is often used as a first-line hormonal therapy.
- Breast Cancer: Constitutes 20%-25%, mainly in premenopausal women.
- Endometriosis and Precocious Puberty: Make up the remaining 10-15%.
Major Regions:
| Region |
Market Share |
Growth Rate (2022-2027) |
Key Drivers |
| North America |
55% |
4% |
Adoption in oncology, health insurance coverage |
| Europe |
30% |
3.5% |
Aging population, increased diagnosis |
| Asia-Pacific |
10% |
6% |
Healthcare expansion, off-label use |
| Rest of World |
5% |
4.5% |
Market access expansion, local manufacturing |
Competitive Landscape: Includes Teva, Ferring Pharmaceuticals, and Licensor companies. The market faces limited generic competition in North America but increasing competition from biosimilars in Europe and emerging markets.
Pricing Trends and Projections
Historical Pricing: As of 2022, average retail price per dose (1-month supply):
| Region |
Approximate Price |
Notes |
| United States |
$4,500 |
Marketed prices, insurance discounts apply |
| Europe |
€3,800 |
European prices tend to be lower, variable |
| Asia-Pacific |
$2,500 |
Lower due to emerging markets and local generics |
Pricing Drivers:
- Patent expirations for key formulations have begun in select markets, leading to price reductions.
- Entry of biosimilars and generics expected to reduce prices by 20-40% over 3-5 years.
- Reimbursement policies influence retail price stability, especially in the U.S. and Europe.
Price Projection (Next 5 Years):
| Year |
Expected Average Price per Dose |
Factors Influencing Price Changes |
| 2023 |
$4,300 |
Slight decline, market stabilization |
| 2024 |
$4,100 |
Biosimilar market entry begins |
| 2025 |
$3,900 |
Increased competition, patent cliffs |
| 2026 |
$3,600 |
Biosimilar proliferation, price erosion |
| 2027 |
$3,200 |
Continued biosimilar adoption, price competition |
Assumptions: Market introduction of biosimilars occurs progressively from 2024; regulatory hurdles are minimal; manufacturers pursue cost reductions and value-based pricing strategies.
Regulatory and Patent Landscape
- Patent expiration in North America: 2021-2022, leading to increased generic availability.
- Biosimilar approval in Europe: Ongoing since 2020, with several candidates approved or pending.
- Regulatory pathways in emerging markets facilitate quicker biosimilar entry, adding downward pressure on prices.
Key Considerations for Stakeholders
- Market Entry: Biosimilar manufacturers targeting regions with patent expiry could capture significant share.
- Pricing Strategies: Existing manufacturers may maintain premium pricing in high-income regions based on brand loyalty and clinical differentiation.
- Supply Chain: Ensuring manufacturing capacity and IP strategy are critical to mitigate impact from biosimilar competition.
Summary
The market for NDC 24208-0485 (Zolodex) is mature with steady demand in oncology and hormone-related conditions. Pricing will decline over the next five years driven by biosimilar competition and patent expiries, particularly in Europe and North America. The total market will experience moderate growth, primarily in emerging regions, aided by healthcare infrastructure expansion.
Key Takeaways
- Global market size stood at ~$1.3 billion in 2022 and is expected to grow at approximately 3-4% annually.
- North American and European markets dominate, but Asia-Pacific presents growth opportunities.
- Prices are projected to decline 20-30% through 2027 due to biosimilar adoption, with regional variations.
- Patent expiries and biosimilar entry are primary catalysts for price erosion.
- Manufacturers should prepare for increased competition by optimizing manufacturing efficiencies and strategic partnerships.
FAQs
Q1. What are the main competitors for NDC 24208-0485?
Generic versions and biosimilars from companies such as Sandoz, Biocon, and Samsung Bioepis are entering the market, especially in Europe and Asia.
Q2. How does patent expiry affect pricing in key markets?
Patent expiry allows biosimilars to enter, increasing competition and significantly lowering prices—typically by 20-40% over a few years.
Q3. Which regions show the most growth potential for this drug?
Asia-Pacific and Latin America exhibit faster growth due to expanding healthcare infrastructure and less regulated markets for biosimilar entry.
Q4. Are there upcoming regulatory changes that could impact prices?
Yes, increased acceptance of biosimilars under streamlined approval pathways, especially in Europe and Asia, will influence pricing.
Q5. How should manufacturers prepare for market changes?
Anticipate biosimilar competition by investing in cost-efficient manufacturing, fostering strategic licensing agreements, and differentiating through clinical or delivery innovations.
References
[1] MarketResearch.com, "Global Oncology Drugs Market," 2022.
